Prelude Therapeutics Advances Pipeline with Phase 1 Study Initiation and Extended Cash Runway
Event summary
- Initiated Phase 1 study of PRT12396, a mutant-selective JAK2V617F inhibitor, for polycythemia vera and myelofibrosis.
- Expects to file IND for PRT13722, a first-in-class KAT6A degrader, by mid-2026 with Phase 1 study initiation in ER+ breast cancer anticipated in the 2H 2026.
- Presented preclinical data for PRT13722 at the AACR Annual Meeting 2026.
- Appointed Charles Morris, M.D. as Chief Medical Officer in April 2026.
- Extended cash runway into the second quarter of 2028, driven by a $90 million underwritten offering.
The big picture
Prelude Therapeutics is advancing its precision oncology pipeline with the initiation of a Phase 1 study for PRT12396 and progress towards IND filing for PRT13722. The company's extended cash runway into 2028 provides a buffer for continued R&D activities. The strategic focus on mutant-selective inhibitors and targeted protein degradation aligns with broader industry trends towards more precise and effective cancer therapies. The appointment of a new Chief Medical Officer and participation in key investor conferences underscore Prelude's commitment to executing its strategic priorities.
What we're watching
- Clinical Progress
- How the Phase 1 study of PRT12396 will impact the treatment landscape for myeloproliferative neoplasms.
- Regulatory Milestones
- Whether Prelude can secure IND approval for PRT13722 and initiate Phase 1 studies in ER+ breast cancer by the end of 2026.
- Financial Sustainability
- The pace at which Prelude will need to secure additional funding to extend its cash runway beyond 2028.
Related topics